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Abstract 11 
One of the most common characteristics of cancer genomes is their aberrant architecture, 12 
ranging from small insertions or deletions to large chromosomal alterations. Chromosomal 13 
instability (CIN) underpins much of the intra-tumoural heterogeneity observed in cancers 14 
and drives phenotypic adaptation during tumour evolution. There is an urgent need to 15 
increase our efforts to target CIN as if it were a molecular entity. Indeed, CIN accelerates 16 
drug resistance acquisition, tumour relapse and treatment failure that plagues current 17 
therapies. Identifying novel strategies to modulate CIN and to exploit the fitness cost 18 
associated with aneuploidy in cancer is therefore of paramount importance for the success 19 
of cancer medicine. Modern sequencing and analytical methods greatly facilitate the 20 
cataloguing of somatic copy number alterations (SCNAs) and offer new possibilities to better 21 
exploit the dynamic process of CIN. Here we will review the principles governing CIN 22 
propagation in cancer, how CIN may impact on immune checkpoint blockade therapy and 23 
survey vulnerabilities associated with CIN that could offer therapeutic opportunities. 24 
 25 
Introduction 26 
Aneuploidy is one of the most striking and widespread features of human cancers, with the 27 
vast majority of tumours displaying various types of SCNAs including segmental 28 
aneuploidies, focal events, or whole-chromosome aneuploidies. Considering only the most 29 
frequent cancers, approximately 60% of lung tumors, 60-80% of breast tumors, 70% of 30 
colorectal tumors and 30 % of prostate tumors deviate from a diploid karyotype1-6. Tumours 31 
that do not feature gross aneuploidy often display hypermutation due to mismatch repair 32 
deficiency or POLE/POLD mutations, which may reflect the limits that cancer cells can 33 
handle in terms of genetic instability7. CIN refers to the ongoing acquisition of genomic 34 
alterations that can involve gain or loss of whole-chromosomes (w-CIN) or structural 35 
aberrations (s-CIN), which range from point mutations to small-scale genomic alterations 36 
and gross chromosomal rearrangements. However, aneuploidy (an aberrant genomic state) 37 
and CIN (the property of displaying a high rate of genomic changes) may differ in their 38 
prognostic value, a distinction that warrants careful investigation. In this review, we will 39 
discuss how CIN impacts upon tumour evolution, provide an overview of the causes of CIN 40 
in cancer with an emphasis on the mechanisms enabling CIN propagation, and strategies to 41 
target CIN in cancer. 42 
 43 
CIN:opening Pandora’s box 44 
 45 
Mitotic causes of CIN 46 
 2 
CIN cells acquire a high rate of SCNAs during cancer cell proliferation, creating genetic 1 
heterogeneity within the population. A myriad of defects can result in frequent 2 
missegregation of chromosomes during cell division. These mechanisms and their causative 3 
role in cancer have been reviewed in detail previously8,9. They include defects that directly 4 
impinge on the chromosome segregation machinery, such as altered microtubule spindle 5 
dynamics, mechanisms required to correct erroneous microtubule-kinetochore 6 
attachments, and defects affecting the mitotic checkpoint or sister-chromatid cohesion8-14. 7 
Supernumerary centrosomes are frequent in cancer and threaten genome stability 8 
by increasing the probability of creating merotelic attachments, a type of microtubule-9 
kinetochore attachment defects that does not trigger the mitotic checkpoint12,15. Failure to 10 
cluster extra centrosomes into two poles leads to a multipolar division, most likely lethal 11 
due to an excessive loss of chromosomes15-18 (Figure 1).  12 
Genome-doubling or tetraploidization, which may arise from a cell division failure or 13 
endoreplication (re-replication without intervening mitosis) amongst several mechanisms19, 14 
directly impair chromosome segregation fidelity during ensuing divisions due to the 15 
presence of extra centrosomes15,20 (Figure 1). Tetraploidization is not only linked to cancer 16 
development but is also part of the normal development program of differentiated cell 17 
types such as hepatocytes, or megakaryocyte and placental trophoblasts which can become 18 
highly polyploid. In addition, tetraploidy is found in ageing tissues and in response to various 19 
stresses21,22. Genome doubling is a frequent feature of human cancers, reported in over 40% 20 
of lung, head and neck, breast, bladder, colorectal, oesophageal and ovarian cancers2,23,24. 21 
Of note, sequencing-based studies can identify tumors that have undergone WGD during 22 
their development, even if the ploidy is no longer tetraploid at diagnosis due to 23 
chromosome losses. This explains the possible discrepancy with cytometry-based studies 24 
where estimates are based on cells carrying an exact tetraploid DNA content. For example, 25 
computational approaches using genomics estimated that over 50% of breast cancer2 had 26 
undergone WGD, while a large scale cytometry-based study detected tetraploid cells in 32% 27 
of tumors25. Genomics studies suggest that genome-doubling is a relatively early event in 28 
the evolution of several cancers and precedes the acquisition of additional SCNAs and 29 
subclonal expansion23,24,26,27. Tetraploid cells have also been detected in pre-malignant 30 
lesions in oesophageal, cervical, breast and head and neck cancers25,28-30. Genome doubling 31 
could therefore represent the CIN-initiating event in an important proportion of human 32 
cancers.  33 
 34 
Structural defects trigger CIN  35 
Aneuploid tumours almost invariably display both numerical and structural chromosomal 36 
aberrations. Pre-mitotic defects such as replication stress can generate chromosome fusions 37 
resulting in dicentric chromosomes (telomere fusion for example) and acentric chromosome 38 
fragments, both of which may be randomly distributed to daughter cells31. DNA bridges 39 
from dicentric chromosomes can also physically prevent cell division and generate 40 
tetraploid cells which are inherently prone to CIN32-35. Under-replicated regions may also 41 
prevent the physical separation of chromosomes during mitosis, leading to aneuploidy36. 42 
Numerical chromosomal aberrations can be symptomatic of DNA replication stress without 43 
underlying defects in the chromosome segregation machinery. Replication stress therefore 44 
provides an alternative route to generate complex karyotypes through the uneven 45 
distribution of damaged genetic material during division.  46 
 47 
 3 
wCIN, sCIN and nuclear envelope defects 1 
Recent studies indicate that missegregated chromosomes are prone to accumulate 2 
mutations and structural defects. For example, mitotic errors can result in lagging 3 
chromosomes during the partitioning of DNA into daughter cells, which may become 4 
trapped during cell division or isolated and form micronuclei. Both situations create a 5 
context whereby the DNA may sustain extensive DNA damage and chromosomal 6 
rearrangements including chromothripsis 37,38. Interestingly, micronuclei and DNA bridges 7 
both display nuclear envelope (NE) disruption and therefore loose compartmentalisation 8 
with the cytoplasm, potentially exposing DNA to reactive oxygen species and cytoplasmic 9 
enzymes. In micronuclei, aberrant DNA replication correlates with NE collapse, the massive 10 
accumulation of DNA damage and chromothripsis37-39. Importantly these observations are 11 
not limited to in vitro analyses, as micronuclei displaying disrupted NE and DNA damage 12 
accumulation could readily be found on NSCLC paraffin samples39.  13 
NE integrity is also lost when dicentric chromosomes create ultrafine bridges, which 14 
can also lead to chromothripsis and hyper-mutation (kataegis) of localized chromatin 15 
regions40. NE loss exposes ultrafine bridges to a cytoplasmic nuclease creating single 16 
stranded DNA, the substrate for mutagenic APOBEC3 enzymes, which could explain the 17 
APOBEC mutational signature often found near rearrangement breakpoints40,41. The 18 
physical yet often transient isolation of DNA during CIN may contribute to the highly 19 
localized nature of APOBEC-driven mutations in cancer, as well as its appearance following 20 
the onset of CIN during tumour evolution42-44. 21 
 Interestingly, cell migration through tight spaces and excessive cytoskeletal forces 22 
exert pressure onto the nucleus, leading to NE rupture, chromatin extrusion, DNA damage45-23 
47 and karyotypic abnormalities47. The process of epithelial-to-mesenchymal transition 24 
induced by TGF- often associated with metastasis, was also linked to chromosomal 25 
instability and NE defects48. Physical constraints and paracrine effects associated with 26 
cancer cell dissemination therefore provide additional routes to genomic instability. 27 
 28 
Cancer cell-extrinsic causes of CIN  29 
Additional cell-extrinsic or non-genetic causes of CIN have also been proposed, besides 30 
mechanical forces upon the nucleus and paracrine induction of EMT described earlier. 31 
Glucose deprivation, hypoxia or acidification of the extracellular milieu, which mimic 32 
properties of the tumour microenvironment, induce genomic instability and aneuploidy49,50. 33 
Entosis, the process of cell engulfment by another cell, causes tetraploid and CIN by 34 
blocking division of the host cell, has been reported to be present at low frequency in 35 
human tumour specimens51,52. 36 
 37 
In summary, chromosome segregation errors can potentially trigger a chain of events 38 
resulting in extensive numerical and structural chromosomal aberration, and cause 39 
mutation acquisition. Indeed, there are numerous examples showing that aneuploidy itself 40 
can be a trigger for further chromosomal instability and rearrangements53-55. Aneuploid and 41 
tetraploid cells evolve to gradually accumulate further whole-chromosome and segmental 42 
aberrations with time20,24,34,54-56. Consequently, even infrequent missegregation events in 43 
cancer cells could induce a leap in cell fitness by causing profound copy-number changes 44 
and acquire point mutations. 45 
 46 
Accelerated evolution through CIN and therapy resistance 47 
 4 
CIN provides an efficient means to respond to various selective pressures, as exemplified by 1 
experimental data in various organisms56-59. Rare clones within karyotypically 2 
heterogeneous populations will often outcompete other cells only when facing selective 3 
pressure57, and tetraploidization in particular facilitates the rapid acquisition of copy-4 
number alterations and mutations in response to stressful conditions, leading to increased 5 
fitness56,58. CIN and tetraploidization also confer multidrug resistance, including for some of 6 
the most commonly used chemotherapeutic drugs60,61. Oncogene addiction, the basic 7 
principle for the efficacy of targeted therapies62, can be circumvented by ongoing CIN. 8 
Elegant experiments using inducible mouse models showed that CIN (driven by MAD2 9 
overexpression), when combined with KRASG12D or HER2 oncogenes, consistently contribute 10 
to bypass oncogene addiction upon oncogene withdrawal and facilitates tumour relapse 11 
and persistance63,64. CIN thus offer an escape mechanism following targeted therapy, and 12 
suggests that the loss of driver oncogenic mutations from a copy-number event would not 13 
be as deleterious in cancer cells with ongoing CIN. This represents a conceivable scenario 14 
since ongoing CIN contributes to mutational heterogeneity by causing the loss of 15 
chromosomal regions previously harboring clonal mutations, which has been observed in 16 
lung65 and breast26 cancers. 17 
CIN is also an important driver of parallel evolution. In NSCLC, focal amplification of 18 
driver genes takes place from different alleles in different tumour subclones, a process 19 
termed mirrored subclonal allelic imbalance, indicative of ongoing CIN65. Comparison of 20 
SCNAs in circulating tumour cells (CTCs) and metastatic tumours also revealed convergence 21 
towards common SCNA in patients from various cancer types66. Of note, neither studies 22 
observed convergence at the mutational level, suggesting CIN allows more rapid selection of 23 
driver events than other mutagenic processes in some cancers. Convergence at the copy-24 
number level involving LOH or oncogene amplification have been reported in high-grade 25 
ovarian cancer67. The emergence of resistance during therapy can also proceed through 26 
parallel convergence. Resistance to ERK-inhibition can occur through parallel amplification 27 
of BRAF in divergent clones52, while resistance to a high dose of a PI3Kα inhibitor arose 28 
through parallel convergence on PTEN loss68,69. CIN therefore allows cells to explore 29 
evolutionary trajectories during tumour evolution and adapt to therapy which underlies 30 
treatment failure. Radiation therapy70, as well as many of the most commonly used 31 
chemotherapeutic drugs induce chromosomal instability in vitro71,72. CIN induction was 32 
observed for several classes of anticancer compounds targeting microtubules (Taxol), DNA 33 
damage response pathways (PARP and topoisomerase inhibitors) as well as DNA 34 
intercalating agents (cisplatin) or nucleoside analogues (Gemcitabine). Notably, in some 35 
cases CIN induction was exacerbated when using drug combinations below their respective 36 
IC50 values71. The efficacy of several drug used as standard of care could be linked to their 37 
common effect of driving excessive genomic instability in cancer cells. Based on this 38 
interpretation, what would make cancer cells exquisitely sensitive to several of these 39 
compounds is not their faster proliferation rate but rather the loss of various checkpoints, 40 
causing them to acquire additional SCNAs beyond a threshold compatible with cell survival 41 
(see CIN Attenuation section below).  42 
 43 
Mechanisms enabling CIN propagation 44 
 45 
Aneuploidy tolerance 46 
 5 
A fundamental difference between normal and transformed cells is in their ability to cope 1 
with genetic imbalances. The deleterious impact of aneuploidy on cellular proliferation has 2 
been documented for many cell types73. For example, in the haematopoietic compartment, 3 
aneuploid cells are outcompeted due to slower proliferation74. Aneuploidy also impairs 4 
organismal development and is the main cause of spontaneous abortions in humans, where 5 
most constitutive aneuploidies are embryonic lethal with trisomy 21 being a rare 6 
exception75. Aneuploidy has profound consequences of gene dosage by causing imbalances 7 
in the expression of hundreds to thousands of genes residing on the extra chromosome(s)76. 8 
This results in a number of aneuploidy-associated stresses that impair overall cellular fitness 9 
by causing metabolic changes and impacting on the protein turnover machinery77-79. 10 
Chromosome gains appear to be particularly detrimental to cell proliferation and tumours 11 
more frequently harbour chromosome losses than gains54. Therefore, it appears that the 12 
aneuploid state itself is not sufficient to transform normal cells and in fact aneuploid cells 13 
are largely under negative selection pressure54,74. Then how to reconcile this observation 14 
with the often-reported high proliferation rate of aneuploid cancer cells? As discussed 15 
below, aneuploidy tolerance mechanisms associated with cell transformation are thought to 16 
enable CIN propagation. There may also be an overestimation regarding the hyper-17 
proliferative feature of cancer cells, symptomatic of in vitro analyses. The proliferation rate 18 
of primary human tumours based on radiographic measurements or derived from tumor 19 
marker levels, suggest their doubling times range from 30 days to several months (reviewed 20 
in 80). These measurements reflect a combination of cellular proliferation and other factors 21 
acting upon cancer cells’ fitness such as immuno-editing, which may mask their actual 22 
proliferative rate. Potential doubling time (Tpot) estimations derived from BrdU 23 
incorporation measurements, also suggest relatively slow doubling times from 1 to 2 days in 24 
head and neck cancer81,82, 4.5 days in colorectal cancer83 and 12.5 to 28 days in breast 25 
cancer84,85. Intravital imaging in immunocompromised mice also shows that cancer cell lines 26 
proliferate significantly more slowly in vivo than they do in cell culture86. The ability of 27 
cancer cells to proliferate despite aneuploidy, even at a slow rate, might be a crucial CIN 28 
determinant more physiologically relevant for tumour evolution. 29 
What might then enable cancer cells to tolerate aneuploidy? Genetic alterations that 30 
improve protein turnover, hence alleviate proteotoxic stress, were reported to improve the 31 
fitness of aneuploid cells87,88. TP53 disruption was proposed as an important mechanism 32 
enabling the propagation of chromosomal instability in vitro and in mouse models. In CIN+ 33 
colorectal cancers for example, TP53 and Adenomatous polyposis coli (APC) mutations, are 34 
the most significantly associated alterations20,31,89-91. Recent studies suggest that p53 does 35 
not invariably arrest cells following chromosome missegregation, and some aneuploidies 36 
can be propagated in a p53-proficient background92,93. One hypothesis is that p53 does not 37 
detect whole-chromosome aneuploidies per se, but some aneuploidies (involving specific 38 
chromosomes, or a combination thereof) generate a level of stress sufficient to induce p53 39 
stabilisation92. On the other hand, the propagation of structural aberrations seems 40 
exquisitely dependent on p53 disruption and linked with the acquisition of complex 41 
karyotypes92,93. P53 stabilisation following chromosome missegregation has been linked to 42 
DNA damage resulting from the entrapment of the chromosome during cytokinesis or from 43 
the aberrant DNA replication and genomics rearrangements occurring within micronuclei94. 44 
The requirement for TP53 pathway disruption for CIN propagation may therefore be 45 
intimately linked to the co-occurrence of DNA damage at sites of chromosomal 46 
rearrangements that link numerical and structural aneuploidies.  47 
 6 
However, classical DNA damage response signalling cannot completely explain CIN-1 
induced p53 stabilisation, and in some experimental conditions stabilisation occurs without 2 
p53 phosphorylation at sites associated with DNA damage and cell cycle arrest cannot be 3 
reverted by ATM inhibitors95. We recently identified Caspase-2 (CASP2) as an upstream 4 
regulator of p53 following chromosome missegregation96. CASP2 was found to cleave 5 
MDM2 in response to chromosome missegregation, known to disrupt MDM2’s ability to 6 
ubiquitinate p53 and targeting it for proteasomal degradation97. In colorectal cell lines, the 7 
CASP2 steady-state level was found to require BCL9L, which acts as a beta-catenin co-factor 8 
for CASP2 transcription. BCL9L mutational inactivation or CASP2 downregulation both 9 
conferred tolerance to chromosomal instability96. Importantly, reduced CASP2 levels also 10 
improved CIN tolerance in p53-deficient cells, by impairing generation of the pro-apoptotic 11 
product tBID. It remains unclear why CASP2 becomes active after chromosome 12 
missegregation. Several pathways therefore converge onto p53 and the apoptotic 13 
machinery to control CIN tolerance in cancer cells, determined by the ability of cells to cope 14 
with global transcriptional and metabolic changes and ongoing genomic rearrangements. 15 
 16 
Tolerance to Genome-Doubling 17 
Genome-doubled cells appear inherently more tolerant to the gain or loss of whole 18 
chromosomes, possibly because the impact on overall gene expression is less than when it 19 
occurs in a diploid cell24,98. The greater ability of genome-doubled cells to buffer the 20 
negative impact of protein imbalances associated with aneuploidy, and their propensity to 21 
CIN due to the presence of extra chromosome(s), may explain why genome-doubling is such 22 
a common precursor of CIN in cancer appearing early in tumour development23,24,27 (Figure 23 
1). However the propagation of genome-doubled cells immediately following cell division 24 
failure is limited at least in part through a p53-mediated G1 arrest99, which may explain why 25 
TP53 mutations are more frequent in genome-doubled tumours and occur prior to genome-26 
doubling100. Activation of the Hippo pathway in response to an increase in centrosomes and 27 
microtubule nucleation was shown to contribute to p53 stabilisation101. However, TP53 28 
disruption is not an obligatory step for the expansion of genome-doubled cells, and several 29 
mechanisms have been described allowing the bypass of TP53 activation. Growth factor 30 
signalling for example, promotes proliferation of tetraploid cells despite engagement of the 31 
p53-p21 axis101. This may be achieved in cancer through activating mutations in PIK3CA 32 
(encoding the p110 catalytic subunit PI3K), which were shown to confer tolerance to 33 
genome doubling (Martin-Berenjeno et al 2017, in press). In breast cancer, PIK3CAH1047R 34 
mutations are predominantly clonal and occur prior to genome-doubling (Martin-Berenjeno 35 
et al. 2017, in press), with a similar association observed in colorectal adenocarcinoma 36 
(PIK3CA mutation)27 and lung squamous-cell carcinoma (chromosome 3q amplification, 37 
which harbours the PIK3CA locus)65. Finally, overexpression of D-type cyclins, which link 38 
mitogenic signalling to cell cycle progression102, allow the circumvention of a G1-arrest 39 
following tetraploidization by quenching p21 resulting from p53 transcriptional activation, 40 
preventing it from exerting its anti-proliferative function103,104. An important mechanism by 41 
which PI3K/AKT and ERK signalling contribute to bypass p53 stabilisation may be through 42 
the up-regulation of D-type cyclins105.  43 
 44 
CIN Attenuation 45 
Cahill and colleagues proposed that genomic instability may contribute to tumour 46 
development only if it does not exceed a threshold beyond which it generates unviable 47 
 7 
karyotypes. It follows the same principles observed in bacterial genetics and virology where 1 
an excessive mutator phenotype has catastrophic consequences106. This concept is 2 
supported by the finding that high SCNA burden and greater intratumour heterogeneity 3 
prior to therapy are associated with improved overall survival, while tumours with 4 
intermediate levels display a poor clinical outcome107-109. Accordingly, CIN can be either 5 
oncogenic or tumour suppressive in mouse models according to the level of instability, 6 
which is affected by the genetic context and the tissue110,111. Elevating chromosome 7 
missegregation rates increases cell death in various cancer cell lines and reduces their 8 
tumorigenic potential112,113. In addition, the efficacy of some cancer treatments that induce 9 
CIN such as taxol and radiation, is improved in cells where the basal rate of chromosomal 10 
instability is higher70,112,114.  11 
The requirement to reach an equilibrium of low CIN may explain the scarcity of 12 
mutations in genes whose disruption robustly induce CIN experimentally, since those would 13 
essentially be under negative selection. Analogous to Muller’s ratchet principle that links 14 
mutation acquisition and species extinction, the accumulation of genomic alterations during 15 
tumour evolution may gradually increase CIN and lead to cancer cell death. It is thus 16 
possible that alterations that limit CIN might be selected for during cancer progression. 17 
Aneuploidy tolerance, although essential for CIN propagation, leaves cells vulnerable to 18 
extreme karyotypic changes, raising the question whether CIN levels can be modulated 19 
during tumour development to mitigate the impact associated with excessive instability. 20 
We reported recently that deleterious mutations in various subunits of the 21 
Anaphase-Promoting Complex/Cyclosome (APC/C) are selected for in cancer, and showed 22 
that monoallelic inactivation of various subunits significantly reduced the rate of 23 
endogenous segregation errors in cancer cell lines95. APC/C dysfunction delayed mitotic 24 
progression only by 5 to 10 minutes, which was sufficient to significantly improve 25 
chromosome segregation fidelity, the fitness of tetraploid cells and reduce the frequency of 26 
merotelic attachment errors, considered a main cause of w-CIN12 (Figure 1). Although 27 
cancer cells divide much less frequently in vivo than in vitro, intravital imaging studies 28 
suggest that the total duration of the mitotic phase itself is unchanged in vivo (~1h)86, 29 
similar to that reported for various cell types in mouse embryos115. Pharmacological in vitro 30 
induction of extreme CIN rapidly selected for cells with APC/C mutations or reduced activity, 31 
translating into a 10-minute mitotic delay. The plasticity in mitotic duration, which merely 32 
affects the overall proliferation rate, offers an effective mechanism to attenuate many CIN-33 
causing defects95. Delaying mitotic progression also improves tetraploid cell fitness by 34 
facilitating centrosome clustering which reduces the frequency of unviable multipolar 35 
divisions16,95,116. Mitotic biomarkers such as MPM-2 and phospho-Histone H3 may therefore 36 
not be optimal to determine the proliferation index on fixed samples. Secondary alterations 37 
that improve cell fitness by reducing CIN may therefore be acquired during tumour 38 
evolution. Mild alterations in mitotic duration due to genetic or epigenetic regulation of 39 
critical mitotic regulators may provide an effective mechanism to fine-tune the level of CIN 40 
to optimise cancer cell fitness. 41 
A crucial determinant for CIN propagation therefore relies on the capacity of cancer 42 
cells to tolerate a given rate of instability, and disruption of this equilibrium is likely to 43 
impair cell fitness (Figure 2). For example many cancer cell lines that display a stable 44 
karyotype missegregate chromosomes at non-negligible frequencies, yet these events are 45 
not tolerated leading to cell death and clearance of aneuploid cells96 (Figure 2). For 46 
example, APC-mutated organoids show a high rate of segregation errors (and would appear 47 
 8 
aneuploid by FISH), but the aneuploid progeny is not propagated efficiently and the 1 
population does not become fully aneuploid unless TP53 is disrupted91. Reduced instability 2 
in evolved tetraploid cells can also be achieved by eliminating the extra centrosomes15,104. 3 
Buffering CIN rates is also a recurrent observation upon mathematical modelling the 4 
evolutionary dynamics of genetically unstable populations, and cell fitness is improved 5 
when CIN rates are reduced117-119. Identifying additional mechanisms driving CIN adaptation 6 
and tolerance may therefore reveal new strategies to target CIN therapeutically. 7 
 8 
Interplay between immunosurveillance and CIN 9 
A complex picture is emerging whereby CIN could impact on cancer cell recognition by the 10 
immune system in multiple and opposing ways. 11 
Immune evasion may be particularly crucial for chromosomally-unstable tumours 12 
since the genomic alterations and stresses associated with aneuploidy may increase their 13 
immunogenicity. A recent analysis of 5,255 tumours and normal samples from TCGA 14 
revealed that high level segmental or whole-chromosome SCNAs in tumours correlate with 15 
reduced expression of gene signatures associated with adaptive immunity and cytotoxic 16 
CD8+ T-cell/NK cells, suggestive of reduced immune infiltration120. Although these 17 
observations remain to be validated in vivo, it supports the notion that the tumour 18 
microenvironment of highly aneuploidy tumours is immunosuppressive, which is supported 19 
by a lower frequency of neoantigen editing in CRC120. 20 
General features shared by CIN cells may constitute an immunogenic trigger. This 21 
effect may in part be driven by endoplasmic reticulum-associated stress in polyploid cells 22 
resulting in extracellular exposure of calreticulin and recognition by cytotoxic T-cells and NK 23 
cells121,122. Pharmacological induction of CIN using an Mps1 inhibitor induced a pro-24 
inflammatory gene signature, increased cytokine secretion, cell surface expression of NK-25 
activating ligands and efficient clearance by NK92 cells in co-culture assays93. In mice, 26 
combining an Mps1 inhibitor with anti-PD1 therapy potentiated tumour regression, 27 
although it is unclear if immunogenicity was triggered by apoptotic cell death or by a feature 28 
of highly aneuploid cells caused by Mps1 inhibition123. Defects in nuclear envelope integrity 29 
from micronuclei DNA, chromatin bridges or during cell migration, were recently shown to 30 
allow DNA recognition by cytosolic cyclic GMP–AMP synthase (cGAS), a crucial sensor of 31 
double-stranded DNA that mediates type I interferon immune responses124,125. This led to a 32 
pro-inflammatory program downstream of STING (stimulator of interferon genes), known to 33 
promote anticancer T-cell responses126. ER-stress and transient cytosolic DNA exposure 34 
associated with CIN are two mechanisms that may trigger a cell-intrinsic innate immune 35 
reaction against chromosomally unstable cells. 36 
Alternatively, CIN could generate tumour-specific neoantigens, which are targeted 37 
by activated T-cells in response to checkpoint blockade127 or during adoptive T-cell 38 
therapy128. The efficacy of immune checkpoint blockade therapy has been associated with a 39 
high mutational burden from non-synonymous single-nucleotide variants (nsSNVs, causing 40 
single amino-acid substitutions), such as reported in melanoma, NSCLC, and cancers with 41 
DNA mismatch-repair deficiency129. As discussed earlier, CIN cells are prone to accumulate 42 
mutations, but this is unlikely to significantly increase nsSNV burden. Genomic 43 
rearrangements associated with CIN on the other hand, especially chromothripsis and 44 
chromoplexy130, could potentially generate many frameshifts in a single catastrophic event. 45 
By analysing tumour mutational spectra in a pan-cancer study, we found that frameshifts 46 
may represent a strong trigger for antitumour T-cell reactivity131. Frameshifts result in the 47 
 9 
expression of aberrant neopeptides of various lengths which, upon processing by antigen-1 
presenting cells, can potentially generate a much larger number of neoantigens compared 2 
to point mutations. This may explain why renal clear cell carcinomas, which have a low 3 
nsSNV burden but a high frameshift burden, respond to checkpoint inhibitor therapy131. The 4 
contribution of complex rearrangements as a source of neopeptides, and their impact on 5 
checkpoint inhibitor efficacy warrants further investigation. 6 
 However, ongoing CIN during checkpoint blockade therapy may also lead to 7 
treatment failure. Indeed, checkpoint inhibitor resistance in NSCLC was recently linked to 8 
the loss of reactive cancer neoantigens through loss-of-heterozygosity132. This may be 9 
expected since CIN underpins the frequent loss of clonal mutations during NSCLC 10 
evolution65. 11 
Further studies are needed to understand the global impact of CIN on 12 
immunosurveillance, considering the metabolic stresses associated with aneuploidy, the 13 
immunogenicity associated with segregation errors as well as CIN’s impact on neoantigen 14 
generation and elimination. While CIN induction prior to checkpoint blockade therapy may 15 
improve response, it may prove crucial to mitigate CIN during treatment to avoid resistance 16 
acquisition.  17 
 18 
Leveraging CIN for cancer treatment 19 
 20 
Challenges in identifying CIN biomarkers 21 
A major limitation in our ability to specifically leverage CIN for prognostic and therapeutic 22 
purposes is the current lack of biomarkers to adequately capture the dynamics of the CIN 23 
phenotype, rather than the static nature of aneuploidy. DNA ploidy assessment using 24 
image-based cytometry or flow cytometry efficiently detect severe aneuploidies and 25 
tetraploidy, provide an indication of heterogeneity between tumour cells and are useful to 26 
determine absolute copy-number from sequencing data 133. However, they lack resolution, 27 
fail to detect s-CIN or low w-CIN rates especially in near-diploid samples. Nuclear 28 
morphological defects on mitotic cells and micronuclei represent a surrogate for 29 
segregation errors. Cytogenetics methods relying on analysis of metaphase cells cannot be 30 
applied in a clinical setting, and FISH-based methods can only detect specific translocations 31 
or measure centromeric modal deviation for limited number of chromosomes at once134. 32 
Copy-number analysis using array-CGH or DNA sequencing from bulk samples essentially 33 
reveal clonally-selected alterations within any given tumour region, and fail to detect 34 
heterogeneity. This is illustrated by the illusion of diploidy observed when analysing highly 35 
aneuploid populations or after mixing defined aneuploid clones64,135. All those methods 36 
mostly report on the genomic complexity of cancer genomes, but not whether ongoing CIN 37 
is at play, not whether errors are tolerated and propagated.  38 
Multi-region sequencing provides further insight into CIN dynamics, enabling to 39 
distinguish between clonal and subclonal SCNAs, and a high proportion of subclonal SCNAs 40 
is therefore indicative of ongoing CIN during tumour evolution. In NSCLC, tumours where 41 
the majority of SCNA events were subclonal displayed shorter disease-free survival, and 42 
observation independent of clinical factors in a multivariate analysis65. On the other hand, a 43 
high proportion of subclonal mutations, indicative of ongoing mutagenesis, had no 44 
prognostic value. CIN may therefore be a more important driver of cancer progression than 45 
an increased mutation rate, a provocative thought that warrants further investigation. 46 
 10 
Analysis of circulating tumour cells (CTCs) or tumour-derived cell-free DNA (cfDNA) 1 
from liquid biopsies offers an amenable way to track SCNA evolution during cancer 2 
progression and treatment66,136-138. In particular low-coverage sequencing on CTCs provides 3 
a non-invasive way to assess tumour heterogeneity at the single cell level to infer CIN66. 4 
Obviously, single cell genomics provides the ultimate level of resolution to fully appreciate 5 
the extent of heterogeneity, and represents the most promising avenue to develop clinically 6 
applicable biomarkers for CIN139. Combining DNA image cytometry and multi-region 7 
sequencing could be exploited to drive he identification of robust biomarkers capable of 8 
capturing CIN dynamics particularly in samples with low cancer cell fraction, which is crucial 9 
if we are to leverage CIN for stratification purposes or to exploit it for direct therapeutic 10 
intervention.  11 
 12 
CIN in Clinical trials 13 
Considering the pervasiveness of CIN in cancer and the consequences of tumor 14 
heterogeneity for cancer treatment, there is currently a very limited number of clinical trials 15 
(reported on clinicaltrials.gov) that either directly investigate the impact of CIN, explore 16 
ways to leverage CIN therapeutically or monitor CIN during disease progression or therapy. 17 
One trial (NCT03096418) is directly investigating whether paclitaxel increases CIN levels in 18 
breast tumors, as suggested from initial studies114, and whether breast cancers with CIN 19 
may be more sensitive to further instability resulting from neoadjuvant therapy. In this 20 
study, the level of aneuploidy and CIN will be measured by parallel methods including 21 
whole-genome sequencing and FISH on independent core samples per biopsy. In addition, 22 
clinical response will also be correlated with tumor levels of paclitaxel (measured by HPLC) 23 
as well as proliferative (Ki-67) and mitotic (phospho-Histone H3) biomarkers. A recently 24 
completed trial (NCT00512642) involving Lung Imaging Fluorescence Endoscopy (LIFE) to 25 
detect early lung lesions in high risk patients involved the collection of analysis of p53 status 26 
and genomic instability (aneuploidy) when lesions were found. Studying CIN in pre-27 
malignant and early disease could be further explored for specific cancer types, such as in a 28 
current study investigating the correlation between ploidy and recurrence in early rectal 29 
cancer (NCT03039595). Another interesting line of investigation worth exploring is to 30 
examine the occurrence of CIN in resection margin as predictor of relapse, similar to what 31 
has been done in a study of oral squamous cell cancer140. 32 
 33 
Perspectives for Targeting CIN cancers 34 
Given the far-reaching consequences of CIN for treatment success and outcome, several 35 
approaches have been explored to target CIN, taking advantage of features associated with 36 
the aneuploid state or their capacity to sustain further instability.  37 
 Reducing fitness of aneuploid cells may be achieved using compounds that 38 
exacerbate the proteotoxic stress (the Hsp90 inhibitor 17-AAG) and metabolic stress (the 39 
AMPK agonist AICAR) associated with aneuploidy, which have shown some selectivity 40 
against aneuploid and CIN cells87,141. Aneuploid and CIN cell lines were recently found to 41 
contain higher levels of ceramides, a class of pro-apoptotic sphingolipids synthesised on the 42 
ER142, and consequently were more sensitive to pharmacological increase in ceramide 43 
levels143. This may explain the reported synergy between conditions that increase ceramide 44 
levels and paclitaxel, which induces chromosome missegregation at clinically relevant 45 
doses114,143-145. 46 
 11 
Increasing chromosome missegregation rates to generate unviable karyotypes is 1 
another avenue actively explored. Several groups have developed Mps1 inhibitors aimed at 2 
causing massive aneuploidy by ablating the mitotic checkpoint, which again seems to 3 
synergise with paclitaxel112,123,146. Identifying cancer types exquisitely sensitive to Mps1 4 
inhibitors may prove challenging and relies on the premise that unwanted aneuploidy in 5 
normal tissues would not be propagated. Mps1 inhibitor efficacy may therefore be 6 
restricted to cancers where paclitaxel has proven effective. The success of Mps1 inhibitor 7 
monotherapy may also be limited by the rapid acquisition of resistance as observed in vitro 8 
through Mps1 mutations, APC/C dysfunction and aneuploidy tolerance acquisition95,96,147. 9 
Forcing cells with extra-centrosomes (such as genome-doubled cells) into a catastrophic 10 
multipolar division, by preventing centrosome clustering, is also being explored for example 11 
by targeting of the non-essential kinesin HSET15,16,148. By accelerating mitosis, Mps1 12 
inhibitors also impair efficient centrosome clustering and promote multipolarity16,95,116. 13 
Phase I studies are currently ongoing for Mps1 inhibitors (NCT02366949, NCT02138812, 14 
NCT02792465). 15 
Targeting tolerance mechanisms in combination with approaches aimed at 16 
increasing CIN rates may represent an efficient way to limit resistance acquisition and 17 
possibly improve response to DNA damaging agents that also drive excessive CIN. Targeting 18 
pathways that converge onto p53 are particularly relevant, either by reactivating p53 in CIN 19 
tumours, disrupting cyclin D-p21 interaction or by blocking signalling pathways that induce 20 
tolerance. For example, low doses of PI3Kα inhibitors which dampen the low-level pathway 21 
activation upon oncogenic activation of PIK3CA may reduce CIN tolerance and tumour 22 
heterogeneity, and limit the generation of drug-resistant clones. 23 
Reducing tumour heterogeneity by directly suppressing chromosome missegregation 24 
may be confounded by the complexity of the CIN phenotype in established tumours, and 25 
CIN may only be temporarily reduced as was reported upon targeting a CIN-driving process 26 
using an MCAK inhibitor149.  27 
Further studies are needed to understand the evolutionary trajectories of 28 
heterogeneous CIN populations in response to various treatments, which may uncover new 29 
targetable dependencies. A deeper understanding of the biological processes affecting the 30 
fitness of CIN cells combined with the ongoing cataloguing of cancer mutations associated 31 
with subclonal expansion may also identify additional druggable targets. In addition, 32 
whether acute induction of extreme CIN will potentiate antitumour immune responses or 33 
drive resistance to checkpoint blockade warrants further investigation. 34 
Although the prognostic value of aneuploidy has been demonstrated for several 35 
indications, deriving robust approaches to assess whether ongoing CIN is taking place within 36 
a given near-diploid or aneuploid sample may be crucial to efficiently exploit it in a clinical 37 
setting. Indeed, aneuploid cancer cells are not invariably chromosomally unstable and can 38 
maintain a stable yet abnormal karyotype. Discriminating between CIN+ and CIN- regardless 39 
of the ploidy status will potentially inform on the response to therapy and chances of 40 
relapse. 41 
 42 
 43 
Conclusion 44 
Development of robust biomarkers capable of capturing CIN dynamics is crucial if we are to 45 
leverage its potential for stratification purposes and to exploit it for direct therapeutic 46 
intervention. Tackling CIN is essential for the success of personalised medicine, a problem 47 
 12 
that is only just beginning to be understood from a therapeutic perspective. Great attention 1 
has been given to the extremely diverse causes of chromosomal instability, but tolerance 2 
mechanisms, ripe for exploitation, are starting to emerge as being crucial determinants for 3 
its propagation. 4 
 5 
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FIGURE LEGENDS 1 
 2 
FIGURE 1 : Merotely, tetraploidy and CIN attenuation. 3 
A) Several types of mitotic defects can lead to chromosome missegregation. Illustrated are 4 
merotelic attachments, whereby one of the sister chromatids is attached to opposite poles 5 
(magenta). These errors are not detected by the mitotic checkpoint, hence mitosis proceed 6 
without delay, resulting in lagging chromosome that can be missegregated to daughter cells. 7 
Severe defects (excessive CIN) generates a high frequency of unviable aneuploid karyotype 8 
that deviates greatly from a 2n diploid content (2n +/- x), due to the loss or gain of too many 9 
chromosomes (red daughter cells). 10 
B) Infrequent segregation errors involving fewer chromosomes likely generate viable 11 
progeny (orange daughter cells), whose proliferation will then depend on various tolerance 12 
mechanisms. The frequency of segregation errors can be attenuated by acquiring secondary 13 
alteration that will improve mitotic fidelity. APC/C dysfunction is one mechanism allowing 14 
cells to delay mitotic progression, giving more time for endogenous mechanisms to correct 15 
attachment errors. 16 
C) Supernumerary centrosomes in tetraploid cells (4n) frequently generate multipolar 17 
spindles and merotelic attachment. Failure to cluster extra centrosomes into two poles will 18 
lead to a multipolar division (4, or 3 daughter cells as shown here) with severe and random 19 
chromosome losses (4n - x). The presence of extra centrosomes also greatly increases 20 
merotely.  21 
D) Tetraploid cells avoid multipolar divisions by achieving centrosome clustering, which 22 
requires the kinesin HSET. Tetraploids are believed to be more tolerant to segregation 23 
errors because it has a milder impact on overall protein stoichiometry, compared to a 24 
diploid cell. Delaying mitotic progression provides more time to achieve centrosome 25 
clustering, and reduces the frequency of segregation errors, improving tetraploid cell fitness 26 
and the propagation of a sustainable rate of CIN (yellow daughter cells). 27 
 28 
FIGURE 2 : Impact of CIN tolerance and attenuation on the propagation of cells with 29 
complex karyotypes. 30 
A) Cells without CIN and functional stress response pathways will maintain a stable 31 
karyotype. Rare stochastic segregation errors will be outcompeted but may persist. 32 
B) CIN in the presence on functional stress response pathways including p53 will prevent the 33 
propagation of cells with complex karyotypes. Only aneuploidies involving specific 34 
chromosomes may be tolerated and will proliferate at a much slower rate. 35 
C) CIN tolerance allows rare stochastic error from an otherwise karyotypically stable 36 
population, to be efficiently propagated. Additional numerical and structural aberration 37 
could be acquired and propagated. 38 
D) Aneuploidy tolerance combined with high chromosomal instability will generate an 39 
increasing number of cells with unviable karyotypes and is therefore tumour suppressive. 40 
E) Alterations causing a transient or less penetrant CIN phenotype will reduce the frequency 41 
of unviable karyotypes. CIN cells may also acquire secondary mutations to reduce the rate 42 
and severity of chromosome segregation errors, improving fitness. 43 


